Allecra Therapeutics
Allecra Therapeutics is a biopharmaceutical company that developed EXBLIFEP (cefepime/enmetazobactam), a novel antibiotic combination approved by the FDA in February 2024 to treat complicated urinary tract infections caused by ESBL-producing bacteria. It commercialized the drug through regional licensing partnerships with hospital and infectious disease specialists.
- Company typePrivate
- Founded2013
- HeadquartersWeil Am Rhein, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Allecra Therapeutics does
Allecra Therapeutics is a biopharmaceutical company founded in 2013 and headquartered in Lörrach, Germany, with a wholly owned French subsidiary (Allecra Therapeutics SAS) in Saint-Louis, France. The company develops novel therapies to combat multi-drug-resistant bacterial infections, with a primary focus on Extended-Spectrum Beta-Lactamase (ESBL)-producing Gram-negative pathogens. Its lead product, EXBLIFEP (cefepime/enmetazobactam), combines a fourth-generation cephalosporin with a proprietary beta-lactamase inhibitor (enmetazobactam) — a tazobactam derivative featuring a strategically placed methyl group and zwitterionic structure that enhances periplasmic penetration and provides superior activity against ESBLs. The combination demonstrated superiority over piperacillin-tazobactam in the Phase 3 ALLIUM trial (79.1% vs 58.9% overall success rate in cUTIs) and received FDA approval in February 2024.
Allecra's business model is built on regional licensing and supply agreements with established pharmaceutical partners for global commercialization: ADVANZ PHARMA holds exclusive rights for Europe, Acino for the Gulf Cooperation Council countries and South Africa, and Shanghai Haini Pharmaceutical for Greater China. Allecra retained direct U.S. rights and sought additional regional partners for unpartnered territories. The company maintained a small operational footprint of 1-10 employees, consistent with an asset-light, licensing-oriented clinical-stage structure. Funding totaled approximately $44.4 million across two disclosed rounds (2013 and 2016), led by Andera Partners, Forbion, Delos Capital, EMBL Ventures, BioMedPartners, and Xeraya Capital, with additional French public funding (Bpifrance and Région Alsace) supporting its French subsidiary.
In October 2025, Allecra was acquired by Orchid Pharma Limited, an Indian pharmaceutical company that reacquired 100% global rights to enmetazobactam. The acquisition transitioned Orchid from a royalty-earning licensor to sole proprietor of EXBLIFEP, which Orchid values at over $1 billion in projected peak sales. This made enmetazobactam the first India-invented New Chemical Entity to receive USFDA approval for a combination antibiotic.
Allecra Therapeutics firmographics
Firmographics- Name
- Allecra Therapeutics
- Legal name
- Allecra Therapeutics GmbH
- Website
- https://allecra.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Allecra Therapeutics is a biopharmaceutical company that developed EXBLIFEP (cefepime/enmetazobactam), a novel antibiotic combination approved by the FDA in February 2024 to treat complicated urinary tract infections caused by ESBL-producing bacteria. It commercialized the drug through regional licensing partnerships with hospital and infectious disease specialists.
- Ownership category
- akta.pro rank
Where Allecra Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Weil Am Rhein
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Allecra Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing and Supply Agreements: Allecra generates revenue through regional licensing and supply agreements with commercial partners for EXBLIFEP/Orblicef. Partners include Acino (GCC and South Africa), ADVANZ PHARMA (Europe), and Shanghai Haini Pharmaceutical (Greater China). Allecra supplies product to its licensees.
- Antibiotic Sales (Post-Acquisition): Following Orchid Pharma's October 2025 acquisition of Allecra Therapeutics, enmetazobactam (as Exblifep/Orblicef) became an approved drug under Orchid's direct commercial control. The combination drug is valued at over $1 billion in projected peak sales.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels3 records
Allecra Therapeutics product offering
Product offeringCore offering
Allecra Therapeutics develops and commercializes novel antibiotic therapies targeting multi-drug-resistant bacterial infections. Its lead product, EXBLIFEP® (cefepime/enmetazobactam), combines a fourth-generation cephalosporin with a proprietary novel beta-lactamase inhibitor to treat complicated urinary tract infections and other infections caused by ESBL-producing Gram-negative pathogens. The drug received FDA approval in February 2024 following a successful Phase 3 ALLIUM trial demonstrating superiority over piperacillin-tazobactam.
Product overview
Allecra Therapeutics is a clinical-stage biopharmaceutical company with a focused product portfolio consisting of its lead antibiotic product EXBLIFEP® (cefepime/enmetazobactam), a novel β-lactam/β-lactamase inhibitor combination. Enmetazobactam is the proprietary β-lactamase inhibitor component that addresses Extended-Spectrum β-lactam resistant pathogens (ESBLs). The company develops therapies to combat antibiotic resistance through overcoming emergent resistance mechanisms. The company has licensing agreements for regional commercialization including with ADVANZ PHARMA (Europe), Acino (Gulf Cooperation Council and South Africa), and Shanghai Haini Pharmaceutical (Greater China).
Differentiator
Problem solved
Functional benefit
Brands
- EXBLIFEP®: Brand name for cefepime/enmetazobactam combination drug approved for treatment of complicated urinary tract infections. Also marketed as Orblicef™ in some markets.
Products and services
- EXBLIFEP® (Cefepime/Enmetazobactam) A novel antibiotic combination drug consisting of cefepime (4th generation cephalosporin) and enmetazobactam (novel beta-lactamase inhibitor) for treating complicated urinary tract infections (cUTIs), hospital-acquired pneumonia, and other serious Gram-negative bacterial infections caused by ESBL-producing pathogens. FDA-approved in February 2024.
- Enmetazobactam A novel proprietary beta-lactamase inhibitor developed by Allecra Therapeutics with potent activity against Class A serine beta-lactamases, specifically Extended-Spectrum beta-lactamases (ESBLs). It is a derivative of tazobactam with enhanced potency, zwitterionic structure for better periplasmic penetration, and extended half-life. Designed for use in combination with cefepime.
Quantifiable outcome
- 79.1% overall success rate for cefepime/enmetazobactam vs 58.9% for piperacillin-tazobactam (21.2% absolute improvement) in complicated urinary tract infections at test-of-cure visit.
- +3 more outcomes
Companies that use Allecra Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Allecra Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Allecra Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- AcinocoreExclusive licensing and supply agreement for Allecra's novel antibiotic EXBLIFEP in Gulf Cooperation Council (GCC) countries and South Africa. Acino is a Swiss pharmaceutical company specializing in licensed-in branded medications for emerging markets.
- ADVANZ PHARMAcoreExclusive license and supply agreement for Allecra's antibiotic cefepime/enmetazobactam in Europe. ADVANZ PHARMA is a pan-European specialty pharma company focused on hospital and critical care medicines.
- Shanghai Haini PharmaceuticalcoreExclusive licensing agreement for cefepime/enmetazobactam for Greater China. Shanghai Haini Pharmaceutical is a Chinese pharmaceutical company focused on licensing and commercializing innovative medicines in China.
Scale indicators5 records
Recent moves7 records
Expansion highlights4 records
Allecra Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Through its acquisition of Allergan's infectious disease unit and Zavicefta (ceftazidime-avibactam), Pfizer competes directly with EXBLIFEP® in ESBL and carbapenem-resistant indications.
- Shionogi: Large Japanese pharma with the cefiderocol franchise (Fetcroja) — a competing siderophore cephalosporin approved for resistant Gram-negative infections. Overlaps with EXBLIFEP® in target patient populations.
- Merck & Co. Markets Zerbaxa (ceftolozane-tazobactam), a direct competitor to cefepime/enmetazobactam for cUTI and intra-abdominal infections, overlapping with Allecra's lead indication.
Direct peers
- Entasis Therapeutics: Anti-infective developer of beta-lactam/beta-lactamase inhibitor combinations targeting resistant Gram-negative pathogens, with a structure analogous to Allecra's enmetazobactam program.
- Paratek Pharmaceuticals: Small/mid-cap anti-infective developer of tetracycline-class antibiotics (Nuzyra) for community-acquired pneumonia and skin infections. Operates with a similar specialty sales force model.
- Iterum Therapeutics: Small-cap anti-infective company developing sulopenem, an oral and IV penem antibiotic for uUTI/cUTI and complicated intra-abdominal infections. Targets similar carbapenem-sparing use cases.
- VenatoRx Pharmaceuticals: Clinical-stage antibiotic developer focused on beta-lactam/beta-lactamase inhibitor combinations for resistant Gram-negative infections. Closely comparable in size, stage and therapeutic target to Allecra.
- Nabriva Therapeutics: Specialty anti-infective company commercializing a recently FDA-approved antibiotic for community-acquired pneumonia and cUTI indications; comparable business model and target prescribers.
- Tetraphase Biosciences: Was a clinical-stage developer of eravacycline (Xerava) for serious infections, an earlier vintage equivalent of Allecra — illustrates the typical size, capital needs, and commercial-build profile for this category.
Others
- Shionogi B. V. / Melinta Therapeutics (Cempra): Adjacent anti-infective specialty players in the same small-cap antibiotic commercialization cohort historically competing in cUTI and respiratory infection markets; comparable in therapeutic positioning though trajectories diverged.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Allecra Therapeutics social profiles
Digital presenceAllecra Therapeutics compliance and trust
Trust signalCompliance2 records
Allecra Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allecra Therapeutics leadership team
Management profileNumber of profiles
Profiles11 records
Allecra Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Allecra Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allecra Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allecra Therapeutics
What does Allecra Therapeutics do?
Allecra Therapeutics develops and commercializes novel antibiotic therapies targeting multi-drug-resistant bacterial infections. Its lead product, EXBLIFEP® (cefepime/enmetazobactam), combines a fourth-generation cephalosporin with a proprietary novel beta-lactamase inhibitor to treat complicated urinary tract infections and other infections caused by ESBL-producing Gram-negative pathogens. The drug received FDA approval in February 2024 following a successful Phase 3 ALLIUM trial demonstrating superiority over piperacillin-tazobactam.
Is Allecra Therapeutics a public or private company?
Allecra Therapeutics is a private company. It is classified as corporate owned and is currently operating.
When was Allecra Therapeutics founded?
Allecra Therapeutics was founded in 2013. It employs 1 to 10 people.
Where is Allecra Therapeutics based?
Allecra Therapeutics is headquartered in Weil Am Rhein, Germany, in the Europe region.
How does Allecra Therapeutics make money?
Two revenue lines are on record. Licensing and Supply Agreements are the primary driver. The others are antibiotic Sales (Post-Acquisition).
Who are Allecra Therapeutics's main competitors?
Broad incumbents on record are Pfizer, Shionogi and Merck & Co.. Direct peers are Entasis Therapeutics, Paratek Pharmaceuticals, Iterum Therapeutics, VenatoRx Pharmaceuticals, Nabriva Therapeutics and Tetraphase Biosciences. Shionogi B. V. / Melinta Therapeutics (Cempra) is listed as an others.
Does Allecra Therapeutics have an API?
No public API is recorded for Allecra Therapeutics.